Celgene keeps M&A pipes flowing in US
US biotechnology company Celgene ensured that August got off to a roaring start for high-grade issuance with an $8bn acquisition financing this week.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: